Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Global Pharma Healthcare Private Limited
WARNING LETTER
•Global Pharma Healthcare Private Limited•March 2, 2023

Global Pharma Healthcare Private Limited – FDA Warning Letter, Mar 2, 2023

Record Details

The FDA issued a Warning Letter to Global Pharma Healthcare Private Limited following a February 20 to March 2, 2023, inspection of their Thiruporur, India facility, identifying significant Current Good Manufacturing Practice (CGMP) violations. This inspection was prompted by a December 2022 multi-state outbreak of antibiotic-resistant *Pseudomonas aeruginosa* infections linked to the company's Artificial Tears products, resulting in patient deaths and vision loss.

FDA testing revealed 18 batches of Artificial Tears and one batch of Artificial Eye Ointment were non-sterile, with *Pseudomonas aeruginosa* isolates from three Artificial Tears batches genetically matching outbreak strains. This intrinsic contamination led to the products being deemed adulterated under 21 U.S.C. 351(a)(2)(A) and (B), and misbranded under 21 U.S.C. 352(j) for non-sterility. Delsam Pharma’s Artificial Eye Ointment was additionally misbranded under 21 U.S.C. 352(a) for falsely claiming sterility.

Key violations included: 1. **Failure to prevent microbiological contamination (21 CFR 211.113(b)):** Inadequate aseptic filling machine qualification, unvalidated sterilization processes (including a contractor's process), insufficient media fills, lack of dynamic airflow studies, and unreliable container-

Company
Global Pharma Healthcare Private Limited
Inspection date
March 2, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Carrie Ann Plucinski
View Company Profile

ID · 79513895-3d08-4ae6-9113-05ac331e8ed6

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)FD&C Act 501(a)(2)(A)21 U.S.C. 351(a)(2)(A)FD&C Act 501(a)(1)FD&C Act 502(j)21 U.S.C. 352(j)

Full citation text and observation details available on the Dashboard.

Other documents for Global Pharma Healthcare Private Limited
  • 483 - 2023-03-02March 2, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Global Pharma Healthcare Private Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.